Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
ETF Frenzy: $875M in Bitcoin, $420M in Ethereum Bought

ETF Frenzy: $875M in Bitcoin, $420M in Ethereum Bought

CoinomediaCoinomedia2025/10/08 10:57
By:Ava NakamuraAva Nakamura

Bitcoin and Ethereum ETFs saw massive inflows on Oct. 7, with $875M BTC and $420M ETH purchases.What’s Driving the Massive Inflows?Bullish Sentiment on the Rise

  • Over $875 million in Bitcoin ETFs were bought on Oct. 7
  • Ethereum ETFs also saw $420 million in inflows
  • Renewed institutional interest signals bullish momentum

October 7 marked a major milestone in the crypto investment space as institutional investors poured massive capital into both Bitcoin and Ethereum ETFs. According to the latest data, around $875.6 million worth of Bitcoin and $420.9 million worth of Ethereum were bought through ETF instruments in a single day.

This significant inflow suggests a growing confidence in digital assets among institutional players, especially following months of regulatory developments and market consolidation.

What’s Driving the Massive Inflows?

The spike in Bitcoin and Ethereum ETF flows comes amid renewed optimism in the broader crypto market . With the potential approval of a spot Bitcoin ETF in the U.S. and a generally more favorable regulatory environment, institutional investors appear to be positioning themselves ahead of what could be a major bull run.

These ETF purchases also suggest that traditional financial players are increasingly viewing crypto as a legitimate asset class. By gaining exposure through ETFs, they avoid the complexities of direct wallet management while still capitalizing on crypto market movements.

🇺🇸 ETF FLOWS: Around $875.6M worth of $BTC and $420.9M worth of $ETH were bought on Oct. 7. pic.twitter.com/7li8DRqOsa

— Cointelegraph (@Cointelegraph) October 8, 2025

Bullish Sentiment on the Rise

The sharp increase in ETF activity could be a key indicator of market momentum. Such large-scale investments often precede broader retail adoption, as institutions tend to lead during early phases of market rallies.

If this pace continues, Bitcoin and Ethereum could see sustained upward pressure in price, further solidifying their roles as core components of diversified investment portfolios.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"

Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.

华尔街见闻•2026/09/29 01:01

Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business

Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.

华尔街见闻•2026/09/29 00:51

AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose

This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.

华尔街见闻•2026/09/29 00:26